Back to Journals » OncoTargets and Therapy » Volume 9

Association between 17q25.3-rs6465657 polymorphism and prostate cancer susceptibility: a meta-analysis based on 19 studies

Authors Jiang X, Zhang M, Bai X, Li S, Wu H

Received 21 January 2016

Accepted for publication 24 April 2016

Published 22 July 2016 Volume 2016:9 Pages 4491—4503

DOI https://doi.org/10.2147/OTT.S104775

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Triparna Sen

Peer reviewer comments 2

Editor who approved publication: Dr William Cho


Xiao Jiang,1,2 Mei Zhang,3 Xiao-Yan Bai,1 Shujing Li,1 Huijian Wu1

1
Laboratory of Molecular Medicine & Pharmacy, School of Life Science and Biotechnology, Dalian University of Technology, Dalian, People’s Republic of China; 2Department of Gastroenterology, Dalian Municipal Central Hospital Affiliated of Dalian Medical University, Dalian, People’s Republic of China; 3Department of Biochemistry and Molecular Biology, Heilongjiang University of Chinese Medicine, Haerbin, People’s Republic of China

Background: Genome-wide association studies have identified rs6465657 polymorphism at chromosome 17q25.3 as a new prostate cancer (PCa) susceptibility locus in people of European descent. However, subsequent replication studies have yielded inconsistent results among different ethnicities. In this study, a comprehensive meta-analysis was conducted to systematically evaluate the relationship between rs6465657 polymorphism and PCa risk.
Methods: All the articles involved were identified from PubMed, EMBASE, Web of Science, EBSCO databases, and Google Scholar before December 2015. The odds ratios (ORs) with corresponding 95% confidence internals (95% CIs) were pooled under the allele model. Fourteen eligible articles with 19 studies were finally included.
Results: In the overall population, the 17q25.3-rs6465657C allele was found to be significantly associated with increased risk of PCa compared to the T allele (OR =1.097; 95% CI: 1.061–1.134; P<0.001). In the subgroup analysis stratified by ethnicity, significantly increased risk was found in the Caucasian population (OR =1.120; 95% CI: 1.078–1.162; P<0.001), while the difference of OR did not reach the statistical significance in the Asian or African-American population. The analyses of sensitivity indicated the robust stability of the results, and the Begg’s and Egger’s test indicated that no publication bias existed.
Conclusion: The current meta-analysis suggested that the 17q25.3-rs6465657 polymorphism could be associated with PCa susceptibility, especially in the Caucasians, while this association might be different in other ethnicities.

Keywords: rs6465657, LMTK2, polymorphism, prostate cancer, risk, meta-analysis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]